首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study.
【24h】

Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study.

机译:日本6644例切除的非小细胞肺癌的预后:一项日本肺癌登记研究。

获取原文
获取原文并翻译 | 示例
           

摘要

For the scheduled future revision of the TNM staging system for lung cancer, it is important that the present 1997 version be evaluated in a large population. In 2001, the Japanese Joint Committee of Lung Cancer Registry sent a questionnaire to 320 Japanese institutions regarding the prognosis and clinicopathological profiles of patients who underwent the resection for primary lung neoplasms in 1994. We compiled the data for 7408 patients from 303 institutions (94.7%). Among these, 6644 patients with non-small cell histology were studied in terms of prognosis. The 5-year survival rate of the entire group was 52.6%. The 5-year survival rates by clinical (c-) stage were as follows: 72.1% for IA (n = 2423), 49.9% for IB (n = 1542), 48.7% for IIA (n = 150), 40.6% for IIB (n = 746), 35.8% for IIIA (n = 1270), 28.0% for IIIB (n = 366) and 20.8% for IV (n = 147). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The 5-year survival rates by pathological (p-) stage were as follows: 79.5% for IA (n = 2009), 60.1% for IB (n = 1418), 59.9% for IIA (n = 232), 42.2% for IIB (n = 757), 29.8% for IIIA (n = 1250), 19.3% for IIIB (n = 719) and 20.0% for IV (n = 259). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The survival curves of stages IB and IIA were almost superimposed in both c- and p-settings. These findings indicated that the present stages IB and IIA should be merged into the same stage category. Otherwise, the present TNM staging system seemed to well characterize the stage-specific prognosis in non-small cell lung cancer. The future revision should focus on the subdivision of stages I and II.
机译:对于肺癌的TNM分期系统的预定的未来修订版,重要的是要在大量人群中评估当前的1997版。 2001年,日本肺癌注册中心联合委员会向320个日本机构发送了一份问卷,调查了1994年接受原发性肺肿瘤切除的患者的预后和临床病理特征。我们汇总了303个机构的7408例患者的数据(占94.7%) )。其中,对6644例非小细胞组织学患者进行了预后研究。整个组的5年生存率是52.6%。临床(c-)期的5年生存率如下:IA(n = 2423)为72.1%,IB(n = 1542)为49.9%,IIA(n = 150)为48.7%,IIA(n = 150)为40.6%。 IIB(n = 746),IIIA(n = 1270)为35.8%,IIIB(n = 366)为28.0%,IV(n = 147)为20.8%。除了IB和IIA之间以及IIIB和IV之间,相邻阶段之间的预后差异显着。病理(p-)分期的5年生存率如下:IA(n = 2009)为79.5%,IB(n = 1418)为60.1%,IIA(n = 232)为59.9%,IIA(n = 232)为42.2% IIB(n = 757),IIIA(n = 1250)为29.8%,IIIB(n = 719)为19.3%和IV(n = 259)为20.0%。除了IB和IIA之间以及IIIB和IV之间,相邻阶段之间的预后差异显着。 IB和IIA期的生存曲线在c和p设置中几乎重叠。这些发现表明,目前的IB和IIA阶段应合并为同一阶段类别。否则,当前的TNM分期系统似乎很好地表征了非小细胞肺癌的分期预后。未来的修订应着重于第一和第二阶段的细分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号